Q-omics provides the consensus-scored RPS7P13 profile across patient tissues and cancer cell-line models. RPS7P13 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS7P13 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RPS7P13 RNA expression shows 2,211 significant pathway-activity associations, with the highest sampling consensus in LUSC. Together, these results highlight KIRP, STAD, and LUSC as cancer lineages where RPS7P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS7P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS7P13 survival associations across molecular data types. RPS7P13 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS7P13 RNA expression–survival associations across cancer types. High RPS7P13 expression shows unfavorable associations in KIRP, UCEC, ACC, PAAD and CHOL, but favorable associations in LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS7P13 RNA expression.
This table summarizes RPS7P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS7P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS7P13 shows higher tumor expression in STAD. The STAD box plot shows higher RPS7P13 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .031).
This table shows molecular features associated with RPS7P13 in patient tissues and cancer cell lines. In patient samples, RPS7P13 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
